ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Gan & Lee Pharmaceuticals Concludes Phase 3 Studies of Gan & Lee Insulin Glargine (GL-GLA)
October 15, 2021Gan & Lee Pharmaceuticals Co., Ltd. (hereinafter referred to as Gan & Lee) (Shanghai: 603087.SH), is pleased to announce the completion of two randomized, multicenter, phase 3 studies ... -
New Data on Phase 1 Proposed Biosimilar Gan & Lee Insulins Aspart (GL-ASP), Lispro (GL-LIS), and Glargine (GL-GLA) Presented at the American Diabetes Association's 81st Scientific Sessions
July 02, 2021Gan & Lee Pharmaceuticals Co., Ltd., announced positive Phase 1 clinical trial results at the 81st Scientific Sessions of the American Diabetes Association (ADA), June 25th – 29th.
Pharma Sources Insight January 2025
